Q2 2021

Filed Aug 10, 2021 · 10-Q · 41 days after period end · 0001539497-21-001192

Q2 2021 · 10-Q

Revenue—

Net Income

-$1.14M

N/M vs Q2 2020

EPS Diluted

-$0.01

N/M vs Q2 2020

Operating Income-$1,042,316N/M

Operating Cash Flowderived-$1,018,591N/M

Same quarter

Metric	Q2 2021	Q2 2020	Q2 2019	Q2 2017
Revenue	—	—	—	$39.47K
Net Income	-$1.14M	-$928.60K	-$130.29K	-$260.42K
EPS Diluted	-$0.01	-$0.01	$0.00	-$0.01

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR